Journal of Hepatology最新文献

{"title":"The first human xenogeneic liver transplantation – A landmark event, but what does it mean for hepatology?","authors":"Heiner Wedemeyer, Frank Tacke, Phil Newsome, Vlad Ratziu","doi":"10.1016/j.jhep.2025.09.015","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.09.015","url":null,"abstract":"No Abstract","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"56 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145247423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Risk of alcohol-related liver disease and cause-specific mortality in individuals seeking treatment for alcohol use disorder”","authors":"Xiong Pei, Dongbo Wu","doi":"10.1016/j.jhep.2025.09.029","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.09.029","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial support</h2>Not applicable.</section></section><section><section><h2>Authors' contributions</h2>XP and DBW: conceptualization and writing original draft; DBW: critical revision for important intellectual content.</section></section><section><section><h2>Conflict of interest</h2>There is no interest to disclose.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"50 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145247421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials","authors":"Carolin Lackner, Annette S.H. Gouw, Venancio Alves, Johanna Arola, Pierre Bedossa, Cynthia Behling, Elisabeth M. Brunt, Alastair Burt, Andrew Clouston, Oscar Cummings, Zachary D. Goodman, Maria Guido, Cynthia Guy, Stefan G. Hubscher, Prodromos Hytiroglou, David Kleiner, Rish Pai, Valerie Paradis, Young Nyun Park, Archana Rastogi, Dina G. Tiniakos","doi":"10.1016/j.jhep.2025.09.019","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.09.019","url":null,"abstract":"<h3>Background &amp; Aims</h3>Assessment of histologic disease activity (grading) and fibrosis (staging) is a prerequisite for patient selection and evaluation of treatment response in clinical trials of metabolic dysfunction-associated steatohepatitis (MASH). The lack of universally accepted definitions of histological components required for metabolic dysfunction-associated disease (MASLD) grading and staging, inconsistent histologic interpretations, and absence of guidelines for the application of currently used scoring systems contribute to high inter-observer variation and also influence supervised machine learning algorithms.<h3>Methods</h3>The International MASLD Pathology Group (IMPG) of 25 expert liver pathologists and a statistician was established to develop guidance for the histological assessment of liver biopsies in MASH for clinical trials and to define standards for processing of liver biopsies as well as to further refine criteria for histological MASLD grading and staging. Statements were generated by three IMPG working subgroups (WG) and were evaluated in a Delphi procedure.<h3>Results</h3>The IMPG WGs issued a total of 278 primary statements which were evaluated in a first Delphi round (DR) yielding 162 statements with 80% or higher agreement. Remaining 116 statements were discussed and revised or not further considered. The resulting 33 revised statements were evaluated in a second DR yielding 192 final statements with 80% or higher agreement.<h3>Conclusion</h3>The IMPG statements provide for the first time guidelines to promote consensus among liver pathologists for the histopathological evaluation and scoring of liver biopsies for MASH clinical trials. Furthermore, they may be used to inform supervised machine learning algorithms for quantitative MASLD histology assessments.<h3>Impact and implications</h3>Inter- (and intra-) observer variations in the histological interpretation of key morphological features of MASH limit the precision of histological grading and staging as well as the diagnosis of the histological MASLD types, MASL and MASH. This is thought to account in clinical trials, at least in part, for screening failure as well as variable placebo response rates, potentially obscuring treatment effects. The International MASLD Pathology Group, consisting of 25 expert liver pathologists, generated consensus statements for histopathological procedures, technical aspects and histological criteria for the diagnosis of MASH, for grading disease activity and staging fibrosis. These may provide a basis for standardized histologic interpretation and the development of AI-based grading and staging algorithms for clinical trials of MASH.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"39 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measuring Health Related Quality of Life and Patient-Reported Outcomes in Chronic Liver Disease","authors":"Zobair M. Younossi, Maria Stepanova, Jörn M. Schattenberg, Linda Henry","doi":"10.1016/j.jhep.2025.09.027","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.09.027","url":null,"abstract":"Chronic liver disease (CLD) is the 11th leading cause of death worldwide, responsible for over two million deaths annually, and the 15th leading cause of disability-adjusted life years (DALYs). To fully capture the burden of CLD, it is essential to assess patient-reported outcomes (PROs) which is defined as patients’ perspectives on their health-related quality of life (HRQL), functional status, daily well-being, and fatigue. Importantly, PROs are self-reported using validated instruments, without interpretation or influence from healthcare providers, family members, or caregivers. Regardless of etiology, patients with CLD consistently report impaired HRQL, reduced work productivity, and difficulty with daily functioning. In fact, these impairments worsen as liver disease progresses but may improve with regression of liver disease due to treatment. Across disease causes, factors most strongly associated with poorer PROs include clinically significant fatigue, anxiety, depression, advanced histologic fibrosis (or non-invasive test [NIT] equivalents), and female sex.In this review, we summarize the historical development and significance of PROs, highlight commonly used PRO instruments [e.g., Short Form (SF)-36, the Chronic Liver Disease Questionnaire (CLDQ), the Work Productivity and Activity Impairment–Specific Health Problem (WPAI-SHP), the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F), EQ-5D], and discuss key considerations for selecting PRO tools(validity, reliability, responsiveness, the minimally clinically important difference). We review the current literature on CLD symptom burden and its relationship with PROs concluding that PRO measurement incorporation into clinical trials and clinical practice is imperative to appreciate patients’ perspectives about their liver disease and/or its treatment. PROs enhance communication between healthcare providers and patients regarding treatment expectations potentially improving outcomes.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"42 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preemptive TIPS in patients with cirrhosis and acute variceal bleeding related to gastric varices: The GAVAPROSEC trial","authors":"Marika Rudler","doi":"10.1016/j.jhep.2025.08.037","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.08.037","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Background and context</h2>In patients with cirrhosis and acute variceal bleeding (AVB), a transjugular intrahepatic portosystemic shunt (TIPS) placed within 72 hours after stabilization should be performed in high-risk patients, such as those with cirrhosis at high risk of rebleeding – specifically, patients with a Child-Pugh score &gt;7 and active bleeding, those with Child-Pugh class C and scores &lt;14, or those with a hepatic venous pressure gradient &gt;20 mmHg.¹ This treatment (preemptive TIPS or pTIPS) has demonstrated a</section></section><section><section><h2>Objectives, methods and findings</h2>The GAVAPROSEC open-label randomized trial¹⁴ was conducted in 105 patients from 17 centers in France. The study included patients with cirrhosis and AVB related to GOV2 or IGV1, comparing pTIPS with variceal glue obliteration combined with NSBBs (control group) as secondary prophylaxis, after stabilization for at least 12 hours. Beyond classical TIPS contraindications, patients with Child-Pugh scores &gt;13 or cavernoma were excluded. Notably, in patients who experienced rebleeding in the control</section></section><section><section><h2>Significance of findings</h2>This large multicenter RCT clearly demonstrated a clinical benefit of pTIPS in terms of rebleeding and rebleeding-free survival, without increasing the rate of HE. However, it failed to show a significant difference in overall survival or further decompensation. The high rate of crossover to TIPS in the control group for rebleeding likely led to an underestimation of the true benefit of pTIPS. Nevertheless, reducing rebleeding is highly significant in case of fundal gastric bleeding, as access</section></section><section><section><h2>Financial support</h2>The authors did not receive any financial support to produce this manuscript.</section></section><section><section><h2>Conflict of interest</h2>Gore, Abbvie, Gilead.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"17 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postnatal hepatocyte proliferation – challenge and opportunity for gene therapy","authors":"Feng Chen, Jan S. Tchorz","doi":"10.1016/j.jhep.2025.09.025","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.09.025","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Conflict of interest</h2>The authors declare there are no conflicts of interest that pertain to this work.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section><section><section><h2>Authors’ contributions</h2>F. Chen and J.S. Tchorz co-authored this article.</section></section><section><section><h2>Declaration of AI and AI-assisted technologies in the writing process</h2>During the preparation of this work the authors used Microsoft Copilot in order to improve readability and language of the manuscript. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.</section></section><section><section><h2>Financial support</h2>None.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"224 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145229327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FGF21 and the brain-liver axis: Harnessing sympathetic pathways in MASH","authors":"Thomas Marjot","doi":"10.1016/j.jhep.2025.08.026","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.08.026","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Background and context</h2>Since the identification of fibroblast growth factor 1 (FGF1) in 1976, the superfamily has grown steadily and now comprises 22 members that exhibit considerable diversity in biological function. FGF21 was originally cloned in 2000 and was the first FGF molecule to be preferentially expressed in mouse liver, hinting towards a physiological role in hepatic function.¹ However, it wasn’t until 2005 that the true extent of its metabolic action began to be recognised with therapeutic administration</section></section><section><section><h2>Objectives, methods and findings</h2>This body of work employed a variety of techniques to characterise a novel FGF21 signalling pathway. This included integrating KLB knockout methods, chemogenetic nerve stimulation, gene expression profiling, and isotopic assessments of lipogenesis across two dietary models of MASH. First, Rose <em>et al.</em> demonstrated that FGF21 administration over 4 weeks prevented weight gain, reduced intrahepatic triglyceride and cholesterol, and improved histological severity of liver injury in diet induced</section></section><section><section><h2>Significance of findings</h2>FGF21 analogues are one of the most likely drug classes to follow resmetirom and GLP-1 receptor agonists into licencing and mainstream clinical practice.³ Efruxifermin, pegozafermin, and efimosfermin alfa are all long-acting once-weekly FGF21 preparations, which have each met primary end-points in phase IIa/b trials, namely improvement in fibrosis with no worsening of MASH or MASH resolution without worsening of fibrosis.[4], [5], [6]^,⁸ Underlying these fibroinflammatory changes appears to be a</section></section><section><section><h2>Financial support</h2>T.M. is supported by a National Institute for Health Research (NIHR) Academic Clinical Lectureship. The views expressed are those of the author and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health.</section></section><section><section><h2>Conflict of interest</h2>T.M. has no conflicts of interest to declare.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"3 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145229307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rat Hepatitis E Virus: An Emerging Challenge in Human Hepatitis","authors":"Katja Dinkelborg, Sébastien Lhomme, André Gömer","doi":"10.1016/j.jhep.2025.09.020","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.09.020","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Conclusion</h2>rHEV is an emerging zoonotic pathogen with many critical questions still unanswered. In this issue, Lo et al. provide important new insights into its zoonotic risk (Box 1). Integration of rHEV testing in Hong Kong identified 22 human infections, while nearly doubling the number of complete human-derived rHEV genomes and enabling an open-access classification system for novel strains. Their findings indicate both adaptation to the human host and genotype-wide zoonotic potential, and the</section></section><section><section><h2>Authors’ contributions</h2>K.D., S.L., and A.G.: Writing – original draft and Writing – review &amp; editing.</section></section><section><section><h2>Financial support</h2>The authors did not receive any financial support to produce this manuscript.</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors do not have a conflict of interest to report.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"76 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145209777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis","authors":"Yu Jun Wong, Laurent Lam, Pierre-Antoine Soret, Sara Lemoinne, Bettina Hansen, Gideon Hirschfield, Aliya Gulamhusein, Ellina Lytvyak, Albert Pares, Ignasi Olivas, Maria-Carlota Londono, Sergio Rogriguez-Tajes, John E. Eaton, Karim T. Osman, Christoph Schramm, Marcial Sebode, Ansgar W. Lohse, George Dalekos, Nikolaos Gatselis, Frederik Nevens, Aldo J. Montano-Loza","doi":"10.1016/j.jhep.2025.09.024","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.09.024","url":null,"abstract":"<h3>Background/aim</h3>Both liver stiffness measurement (LSM) and biochemical response have prognostic significance in patients with primary biliary cholangitis (PBC). However, the frequency and clinical relevance of discordant biochemical and LSM changes remain unclear. We aim to determine the performance of the most recent or current LSM (LSMc) in predicting first hepatic decompensation (HD) in the setting of discordant biochemical and LSM responses.<h3>Methods</h3>In this international, multicenter study, we included patients with at least two reliable LSM performed at least six months apart. Patients with prior HD, liver transplantation (LT) or hepatocellular carcinoma were excluded. Biochemical response was based on the Paris-2 criteria. LSM response was defined as stable or any reduction in LSM. The primary outcome was the occurrence of the first HD. Secondary outcomes were LT and liver-related death. The influence of LSM on HD was estimated using Cox regression analysis.<h3>Results</h3>A total of 1,793 PBC patients were analyzed. Over a median follow-up of 22 (IQR: 12-39) months, 3.3% developed HD. Up to 55% of PBC patients exhibited discordance between LSM and biochemical response. Among patients with LSM response, achieving Paris-2 criteria was associated with a lower risk of HD (HR 0.25, 95%CI: 0.06-0.97, p&lt;0.044). Among patients with biochemical response, LSM response did not influence the risk of developing HD (HR 0.64, 95%CI: 0.21-1.96, p=0.429). The LSMc &gt;10 kPa strongly predicted HD (HR 14.5, 95% CI 6.9-30.6, p&lt;0.001), irrespective of biochemical response and prior LSM trajectories.<h3>Conclusions</h3>Discordance between LSM and biochemical response is frequent. Most recent or current LSM is the strongest predictor of first liver-related events in patients with PBC, irrespective of prior biochemical response or LSM trajectory.<h3>IMPACT AND IMPLICATIONS</h3>Both liver stiffness measurement (LSM) and biochemical response have prognostic significance in patients with primary biliary cholangitis (PBC). However, the clinical relevance and how discordant biochemical and LSM changes should be best interpreted remain unclear. In this large international multicenter study, we demonstrated that once the current LSM (LSMc) is known, prior LSM trajectories and biochemical changes did not improve the prediction of liver-related events in patients with PBC.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"26 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145209776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort","authors":"Hashem B. El-Serag, Camden Lopez, Michelle Luster, K.Rajender Reddy, Neehar Parikh, Amit G. Singal, Jorge A. Marrero, Aaron P. Thrift, Jagpreet Chhatwal, Ziding Feng, Stephanie Page-Lester, Qingchun Jin, Nabihah Tayob, Fasiha Kanwal","doi":"10.1016/j.jhep.2025.09.023","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.09.023","url":null,"abstract":"<h3>Background</h3>We previously developed Hepatocellular Carcinoma Early Detection Screening (HES) V2.0, biomarker panel (age, ALT, platelets, etiology, AFP, AFP L3, DCP and their gradient over the past one year) for early detection of HCC among patients with cirrhosis. We externally validated HES V2.0 and compared its performance to HES V1.0, GALAD, and ASAP.<h3>Methods</h3>We conducted a prospective-specimen collection, retrospective-blinded-evaluation (PRoBE) cohort study in the HEDS (Hepatocellular Carcinoma Early Detection Strategy) 1,485 cirrhosis cohort (119 developed HCC). Patient- and test-level true positive rate (TPR) for HCC were calculated at 6, 12, 24 months before HCC diagnosis based on a threshold at a fixed false positive rate (FPR) of 10% and 18.1% - the latter corresponded to GALAD cut-off of -1.36.<h3>Results</h3>HES V2.0 and GALAD had same AUROC (0.79) but different TPR/FPRs. At the FPR of 10%, HES V2.0 had 2.0%, 6.7%, and 6.0% higher TPR (sensitivity) than GALAD within 6, 12, and 24 months before HCC diagnosis (one-sided p-values 0.24, 0.025, 0.078, respectively). At 18.1% FPR, GALAD had 6% and 2% higher sensitivity than HES V2.0 within 6 and 12 months before HCC and similar sensitivity within 24 months before HCC diagnosis (all p-values &gt;0.05).The sensitivity for HES V2.0 was 11.9% higher than HES V1.0 at 12 months (p=0.007). The sensitivity for HES V2.0 was considerably (10.9-16.3%) higher than ASAP. For patients with available labs to calculate gradients over time, the sensitivity of HES V2.0 was 3.5-8.7% higher than GALAD at all time points of testing before HCC (8.7% to 24.0% relative increase) with p&lt;0.05 for several comparisons.<h3>Conclusions</h3>In a phase 3 biomarker validation study, HES V2.0 had higher sensitivity than ASAP for HCC detection, and a similar or higher sensitivity than GALAD only at 12 months before HCC diagnosis at 10% FPR and when over time gradients in AFP, AFP L3, and DCP are available.<h3>Impact and Implications</h3>Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with early detection being critical for improving survival outcomes. This study provides a rigorous phase 3 validation of the HES V2.0 biomarker panel, demonstrating its superior or comparable sensitivity to established models like GALAD and ASAP in a large, diverse U.S. cirrhosis cohort. The findings are particularly impactful for clinicians and researchers focused on liver cancer surveillance, as HES V2.0 offers enhanced detection performance, especially when longitudinal biomarker data are available. These results support the integration of HES V2.0 into clinical workflows and future trials, potentially improving early HCC detection and enabling timely curative interventions for at-risk patients.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"10 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}